Samsung Biologics (207940) Fundamentals 2026 — P/E 33.8x, Revenue Analysis | SniperIQ
Samsung Biologics (207940) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩63.51T, trading at ₩1372000.00 on the KSC. This SniperIQ fundamentals page covers Samsung Biologics's valuation (P/E 33.8x, P/B 8.0x), profitability (net margin 41.6%), revenue (₩4.56T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Samsung Biologics's market cap?
Samsung Biologics (207940) has a market capitalization of approximately ₩63.51T, trading at ₩1372000.00 on the KSC. Market cap moves with the live share price.
What is Samsung Biologics's P/E ratio?
Samsung Biologics's trailing twelve-month P/E ratio is 33.8x, with a price-to-book (P/B) of 8.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Samsung Biologics?
Samsung Biologics runs a net profit margin of 41.6%, a gross margin of 55.5%, and an operating margin of 41.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Samsung Biologics generate?
Samsung Biologics reported revenue of ₩4.56T for fiscal year 2025, with net income of ₩1.78T and earnings per share (EPS) of 38588. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Samsung Biologics pay a dividend?
Samsung Biologics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Samsung Biologics financially healthy?
Samsung Biologics carries a debt-to-equity ratio of 0.15x and a current ratio of 1.70x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Samsung Biologics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Samsung Biologics (207940) the key facts are: market cap ₩63.51T, P/E 33.8x, revenue ₩4.56T, 52-week range 1228000-1987000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Samsung Biologics's full fundamentals live
Get Samsung Biologics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.